The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Bronchiolitis (a clinical-imaging pattern suggestive of)
Publications
Bronchiolitis of immune checkpoint inhibitor therapy-related pneumonitis.
The American journal of the medical sciences 2022 Sep 23;; — 2022 Sep 23
Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Current oncology (Toronto, Ont.) 2019 Aug;26;e571-e573 — 2019 Aug — e571-e573